Bruker Corporation (BRKR) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, BRKR scores 59 out of 100 (letter grade C-, verdict "Roarable Hold — Cautious Neutral"). The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 1.3%; FCF yield 0.46%); Whale 13F Flow at 17/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 11/20 (Beta 0.97; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.81; Piotroski F 6/9; Debt/Equity 0.75).

The strongest pillar is institutional flow, which is the main upside driver the rating identifies. The weakest pillars are insider conviction and the cash engine. A low ROIC and a sub-1% FCF yield indicate that current cash generation does little to support the share price, so valuation depends heavily on expectations for future earnings. Per the market data, forward P/E is 22 while EV/EBITDA is 75.7, a wide gap that signals a valuation tradeoff: the stock prices in improvement that the trailing financials do not yet show. The Beta of 0.97 places the stock close to market-level volatility, and the sector-sensitivity note in the rating means macro shifts affecting health care instruments could move it. The Forensic Balance Sheet score is moderate, with a Z-Score in the grey-zone range and a Piotroski score of 6/9, suggesting reasonable but not pristine financial health. Overall, the rating reflects a mixed picture: institutional interest and a recovering share price against weak current returns and thin insider signaling.

Bruker Corporation (BRKR) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Laboratory Analytical Instruments industry, per the company profile. The profile states a market capitalization of $9.4B. Per the market data, gross margin is 45.9%, indicating the product mix carries meaningful pricing power at the gross level. Customer and product-level detail, as well as the specific revenue model, are not available in source data.

Per the SEC financials, revenue rose from $2964.5M in FY 2023 to $3436.5M in FY 2025, while operating income fell from $436.9M to $68.2M and net income moved to $-8.3M in FY 2025. Per the market data, operating margin is 2% and net margin is -0.2%, and ROIC is 1.3%. The Roarable rating cites an Altman Z-Score of 2.81 and a Piotroski F-Score of 6/9, with Debt/Equity of 0.75. Debt declined from $2061.8M to $1852.5M between FY 2024 and FY 2025, while cash rose to $298.8M. Per the source, the FY 2023 cash figure is not available.

• Risk Watch (RED): "3 Reasons BRKR is Risky and 1 Stock to Buy Instead" (Yahoo Finance).
• Risk Watch (RED): "Bruker, Sotera downgraded at J.P. Morgan (BRKR:NASDAQ)" (Seeking Alpha).
• Market Wire (YELLOW): "Bruker Corporation Estimates – NASDAQ:BRKR" (TradingView).
• Market Wire (YELLOW): "Bruker Corporation (BRKR) Stock Forecasts" (Yahoo Finance).
• Market Wire (YELLOW): "Bruker (NASDAQ:BRKR) Stock Price Down 6.5% - Time to Sell?" (MarketBeat).
• Catalyst (GREEN): "Bruker Gains 66.3% in a Year: What's Driving the Rally?" (TradingView).

Per the news feed, two items are flagged as risk watch, including a downgrade reported by Seeking Alpha, and one item is flagged as a positive catalyst citing a 66.3% one-year gain. The MarketBeat item references a 6.5% price decline. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," there are no butterfly links, and there are no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream links, sector correlations, or proprietary signals are recorded; the supply chain is listed as "NONE." Upstream/downstream dependencies and 2nd-order bottlenecks are therefore not available in source data. Investors should note this gap, as it removes a structural view of how suppliers, customers, or sector peers might transmit shocks to BRKR. The sector and industry classification (Health Care; Biotechnology: Laboratory Analytical Instruments) is the only contextual link available.

• What is the company's reported EPS for FY 2023–FY 2025? The financials table lists EPS as N/A for all periods.
• What is the trailing P/E? The market data lists it as not available, while forward P/E is 22.
• What drove the change in operating income from $436.9M (FY 2023) to $68.2M (FY 2025) despite rising revenue?
• What is the FY 2023 cash balance, and what is the company's reported business mix by product line and customer type?
• What were the specific reasons behind the J.P. Morgan downgrade and the 6.5% price decline referenced in the news feed?